阿戈梅拉丁在治疗耐药强迫症中的有效性:一项随机对照试验
Azadeh Nejati1, Amir Bazrafshan2, Seyed Hamdollah Mosavat3
1Research Center for Psychiatry and Behavioral Science, Shiraz University of Medical Sciences, Shiraz, Iran.
International journal of psychiatry in medicine
|December 29, 2023
概括
在12周的试验中,阿戈梅拉丁与安慰剂相比,没有显著改善强迫症 (OCD) 症状. 需要进一步的研究来探索其在特定的强迫症患者小组中的潜力.
科学领域:
- 精神病学和药理学 精神病学和药理学
背景情况:
- 强迫症 (OCD) 是一种常见且令人虚弱的心理健康状况.
- 抗治疗的强迫症是一种重大的临床挑战.
- 阿戈梅拉丁是一种色胺和色胺系统调节剂,已被事建议用于治疗耐药性强迫症.
研究的目的:
- 评估阿戈梅拉丁在治疗耐药性强迫症患者中的疗效.
- 在12周的时间内,比较阿戈梅拉丁与安慰剂的影响.
主要方法:
- 一个随机,双盲,安慰剂对照试验,涉及60名患有治疗耐药性强迫症的患者.
- 参与者接受了阿戈梅拉丁50毫克/天或安慰剂.
- 使用耶鲁-布朗强迫症度表 (Y-BOCS) 测量症状严重程度.
主要成果:
- 在agomelatine和安慰剂组之间没有观察到Y-BOCS得分的统计学上显著差异.
- 阿戈梅拉丁在减少强迫症症状方面没有表现出比安慰剂更高的疗效.
- 副作用和肝酶水平相似,在两组中保持在正常范围内.
结论:
- 这项研究没有证实与安慰剂相比,阿戈梅拉丁作为治疗一般性抗治疗性强迫症的优越治疗方法的有效性.
- 需要进一步的研究来探索agomelatine在特定的强迫症患者小组中的潜力.
- 需要进行更广泛和更强大的临床试验,才能充分阐明阿戈梅拉丁在强迫症治疗中的作用.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
239
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
239
Operant Conditioning Intervention
58
Operant conditioning serves as a foundational principle in therapeutic interventions aimed at modifying maladaptive behaviors. Central to this approach is the notion that behaviors, both adaptive and maladaptive, are learned through reinforcement. By analyzing the environmental factors that reinforce problematic behaviors, clinicians can design interventions to weaken these reinforcements and replace maladaptive behaviors with healthier alternatives.
In operant conditioning, behaviors that are...
In operant conditioning, behaviors that are...
58


